Company / Free Cash Flow
Regeneron Pharmaceuticals Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$4.1B
FY2025
5-year range
$2.0B / $4.1B
FY2021-FY2025
Trend
+11.3%
vs FY2024
Sector context
#8 of 194
Health Care
What the data says
Among 194 Health Care companies, Regeneron Pharmaceuticals is in the top 4% for free cash flow. Free Cash Flow has fluctuated over the past 10 years, ranging from $974M in FY2016 to $4.1B in FY2025.
Based on SEC 10-K filings.
$4.1B in FY2025 with a 5-year CAGR of +17.6%. Top quartile in the Health Care sector.
Improved from $3.9B to $4.1B over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- +26.8%
- 5-Year CAGR
- +17.6%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 194This company $4.1B Sector average $470.6M
▼
+767.1% above sector average
Key checks
Key Insights
- 5-year CAGR of +17.6%, indicating consistent growth.
- In FY2025, free cash flow increased 11.3% year-over-year.
- Ranks #8 out of 194 companies in the Health Care sector.
- Lowest free cash flow in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.1B | +11.3% |
| FY2024 | $3.7B | -5.4% |
| FY2023 | $3.9B | +93.4% |
| FY2022 | $2.0B | +0.2% |
| FY2021 | $2.0B | +10.4% |
| FY2020 | $1.8B | -9.4% |
| FY2019 | $2.0B | +10.4% |
| FY2018 | $1.8B | +75.2% |
| FY2017 | $1.0B | +6.2% |
| FY2016 | $974.0M | +49.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026